

Special Issue

COVID-19 and Pregnancy: Prevention and Control Strategies for Coronavirus in Women

Message from the Guest Editor

The novel severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) began in Wuhan, China in December 2019. As of 17 March 2020, 153 countries had reported cases of infection caused by this virus, with Italy becoming the new epicentre. COVID-19 is a global public health emergency and could cause devastating health issues during pregnancy. Interim COVID-19 guidelines for the effective counselling and education of pregnant women are currently available from the Center for Disease Control and Prevention (CDC) and the World Health Organization (WHO). Recommendations which were published following the COVID epidemic in Wuhan are also available from Chinese experts. December 2019. At the same time, the fact that results from studies concerning COVID-19 infection in pregnant and lactating women are being published so quickly may be a limitation of any review of the literature. More original studies regarding infected pregnant women are needed to establish totally evidence-based protocols of care for these patients.

Guest Editor

Dr. Gianluca Straface

Division of Perinatal Medicine, Policlinico Abano Terme, 35031 Abano Terme, Italy

Deadline for manuscript submissions

closed (31 January 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/140320

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).